EWTX
Overvalued by 97.3% based on the discounted cash flow analysis.
Market cap | $1.50 Billion |
---|---|
Enterprise Value | $1.47 Billion |
Dividend Yield | $0 (0%) |
Earnings per Share | $-1.45 |
Beta | 0.37 |
Outstanding Shares | 95,130,053 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -9.3 |
---|---|
PEG | -21.61 |
Price to Sales | - |
Price to Book Ratio | 3.71 |
Enterprise Value to Revenue | - |
Enterprise Value to EBIT | -8.63 |
Enterprise Value to Net Income | -11 |
Total Debt to Enterprise | 0.01 |
Debt to Equity | 0.03 |
No data
No data
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need....